metformin / Generic mfg. - LARVOL DELTA

Complete Response to Tislelizumab in an Elderly Patient With Metastatic Pulmonary Squamous Cell Carcinoma: Potential Synergy With Metformin and Multidisciplinary Management. (PubMed, Clin Case Rep) - "Carefully selected elderly patients with metastatic PSCC may obtain a durable complete response via tislelizumab chemoimmunotherapy combined with metformin and standardized MDT management, providing practical clinical reference for high-risk elderly lung cancer patients complicated with multiple comorbidities."

Journal • Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

Metformin Inhibits Trophoblast Ferroptosis by Suppressing ATF2 and Activating the PI3K/Akt/Nrf2 Pathway to Improve Gestational Diabetes Mellitus. (PubMed, FASEB J) - "In STZ-induced hyperglycemic rats, MET decreased placental ATF2 expression, restored the PI3K/Akt-Nrf2-GPX4 axis, alleviated ferroptosis, and reduced fetal weight. Collectively, our findings indicate that MET suppresses ATF2, activates PI3K/Akt, drives Nrf2 nuclear import, upregulates GPX4, and curbs high-glucose-induced trophoblast ferroptosis, offering new mechanistic insight and therapeutic avenues for GDM."

Journal • Diabetes • Gestational Diabetes • Metabolic Disorders • ATF2 • GPX4

Quercetin alleviates painful diabetic neuropathy in association with gut microbial remodeling and spinal betaine-related metabolic changes. (PubMed, Phytomedicine) - "Quercetin alleviated PDN and was associated with coordinated gut, systemic, and spinal changes. Betaine may represent one candidate functional contributor, although microbiota-specific causality and the directionality of the proposed gut-spinal connection remain unestablished."

Journal • Diabetic Neuropathy • Gastrointestinal Disorder • Immunology • Inflammation • Metabolic Disorders • Pain • GFAP

Real-World Prescribing Patterns and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Empagliflozin-Sitagliptin-Metformin Fixed-Dose Combination Therapy. (PubMed, Cureus) - "Empagliflozin-based triple FDC therapy was prescribed among Indian patients with T2DM, particularly older adults with cardiometabolic comorbidities. Distinct prescribing patterns and clinical characteristics observed between ESM-25 and ESM-10 therapy may reflect individualized treatment selection in routine clinical practice."

Journal • Real-world evidence • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation. (PubMed, BMJ) - "Compared with DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors reduce the risk of deterioration of renal function in people with albuminuria. Little evidence of renal benefit among people without albuminuria was observed over the study follow-up period."

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Renal Disease • Type 2 Diabetes Mellitus

Trust, but Verify: Translating Dosing Evidence to Understudied Populations in Low- and Middle-Income Countries. (PubMed, Clin Pharmacol Ther) - "Using a metformin-dolutegravir drug interaction study and colistin pharmacokinetic study from South Africa, we illustrate how body composition and disease severity, respectively, can alter dosing assumptions. Drug development and post-registration programs should include explicit translation plans using target-population data to confirm, refine, or revise dosing recommendations in understudied target populations."

Journal

Impact of Metformin on Cardiopulmonary Outcomes in Sarcoidosis: A Global Retrospective Cohort Study Using TriNetX (ACR Convergence 2026) - No abstract available

Retrospective data • Immunology • Sarcoidosis

Adding Metformin to First-Line Methotrexate in Methotrexate-Naive Patients with Active Rheumatoid Arthritis: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial (ACR Convergence 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Combined Rapamycin and Metformin Therapy Attenuates Lupus Manifestations While Mitigating Metabolic Toxicity in MRL/lpr Mice (ACR Convergence 2026) - No abstract available

Preclinical • Immunology • Inflammatory Arthritis • Lupus

Cost-Effectiveness of Metformin, Injectable Tirzepatide, and Oral Semaglutide for Patients with Knee Osteoarthritis and Obesity (ACR Convergence 2026) - No abstract available

Clinical • Cost effectiveness • HEOR • Genetic Disorders • Immunology • Obesity • Osteoarthritis • Rheumatology

Toxoplasma GRA16 Potentiates Oxaliplatin Efficacy in Pancreatic Cancer via Redox-Mediated Apoptosis (IASGO 2026) - "Background : Non-alcoholic fatty liver disease (NAFLD) is a clinically significant complication occurringin up to 30% of patients following pancreatic resection, yet its underlying molecular mechanismsremain poorly understood and no established therapeutic guidelines exist. Conclusions : Post-pancreatectomy steatotic liver disease is associated with hepatic circadiandysregulation centered on the ARNTL–PDK4 axis. Metformin reverses this transcriptional programindependently of glycemic control, identifying circadian-metabolic genes as candidate biomarkers andtherapeutic targets warranting clinical evaluation."

Clinical • Addiction (Opioid and Alcohol) • Hepatology • Metabolic Dysfunction-Associated Steatotic Liver Disease • Oncology • Pancreatic Cancer • Solid Tumor • ARNTL • PDK4 • PER2 • PER3

Targeting a New Metabolic-Epigenetic Axis Towards Improved CAR T Therapy in Multiple Myeloma (IMS 2026) - "Together, these findings establish histone glycation as a causal metabolic-epigenetic pathway driving T cell exhaustion and suggest metabolic intervention to improve immunotherapy efficacy in patients with MM."

CAR T-Cell Therapy • Diabetes • Hematological Malignancies • Metabolic Disorders • Multiple Myeloma

Hepatic Circadian Dysregulation via the ARNTL–PDK4 Axis Underlies Post-Pancreatectomy Steatotic Liver Disease and Is Reversed by Metformin (IASGO 2026) - "Conclusions : Post-pancreatectomy steatotic liver disease is associated with hepatic circadiandysregulation centered on the ARNTL–PDK4 axis. Metformin reverses this transcriptional programindependently of glycemic control, identifying circadian-metabolic genes as candidate biomarkers andtherapeutic targets warranting clinical evaluation."

Addiction (Opioid and Alcohol) • Hepatology • Metabolic Dysfunction-Associated Steatotic Liver Disease • ARNTL • PDK4 • PER2 • PER3

APOBEC3B Promotes Mitochondrial and Inflammatory Adaptation Underlying Proteasome Inhibitor Resistance in Multiple Myeloma (IMS 2026) - "Because proteasome inhibition imposes substantial proteotoxic and energetic stress, we hypothesized that A3B promotes mitochondrial fitness and metabolic adaptation during bortezomib (BTZ) treatment. A3B promotes BTZ resistance through mitochondrial metabolic adaptation rather than increased sister chromatid exchange. These findings identify a novel role for APOBEC3B in MM and suggest that A3B-high disease may be vulnerable to OXPHOS-targeting therapies, including metformin-based combinations."

Hematological Malignancies • Multiple Myeloma • APOBEC3A • APOBEC3B • CCL3 • CCND2 • FGFR3 • IL10 • IL6 • PPARGC1A • TNFRSF10D

Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts. (ASCO 2025) - P1 | "Clinical Trial Registration Number: NCT03006172 Background: INAVO, a highly potent and selective PI3Kα inhibitor that also promotes degradation of mutated p110α, is approved by the FDA in combination with PALBO + fulvestrant (FULV) for PIK3CA-mutated, HR+, HER2–, endocrine-resistant advanced BC... Adults ≥ 18 years of age received INAVO alone (Arm A), + letrozole (LET) + PALBO (Arm B), + LET (Arm C), + FULV (Arm D), + FULV + PALBO (Arm E), or + FULV + PALBO + primary prophylactic metformin (Arm F)...The most common anti-HG medications were metformin (52.7%; biguanide; concomitant use in Arm F excluded), empagliflozin (25.5%; SGLT-2 inhibitor), sitagliptin (22.7%; DPP-4 inhibitor), and pioglitazone (13.6%; thiazolidinedione); insulin was used in 8.2% of pts... A high proportion of prediabetic/obese pts were included in GO39374. In most of these pts, HG was manageable with dose interruptions and oral anti-HG medications, most commonly metformin. Data support the use..."

Clinical • Combination therapy • Metastases • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Obesity • Oncology • Solid Tumor • HER-2 • PIK3CA

Hidradenitis-Like Lesions as the Initial Presentation of Multisystem Langerhans Cell Histiocytosis With Liver, Lung, and Central Nervous System Involvement in an Adolescent: Diagnostic Pitfalls and Therapeutic Limitations (SOHO 2026) - "Case Presentation: A 17-year-old boy with hepatic steatosis, prediabetes, and recently diagnosed HS treated with zinc, metformin, and clindamycin, presented with extensive skin lesions...He started LCH-III therapy (vinblastine/prednisone) with improvement in many skin lesions... Severe "HS" with systemic symptoms can create diagnostic and therapeutic gridlock when the true driver is multisystem Langerhans cell histiocytosis (LCH), abruptly limiting HS options (eg, immunosuppression) and rendering surgery nonbeneficial. Early multidisciplinary coordination among dermatology, oncology, surgery, endocrinology, psychology, and social work enables timely biopsy/diagnosis, anticipates treatment constraints, and prioritizes symptom-directed HS care alongside cancer-directed therapy. This abstract was previously presented at Ochsner Research Week 2026, New Orleans, LA, May 21, 2026."

Hematological Malignancies • Oncology • AFP • CD1a

Phase 2 study of letrozole, abemaciclib and metformin in estrogen receptor (ER) positive recurrent endometrial cancer (EC) (SGO 2025) - No abstract available

Late-breaking abstract • P2 data • Endometrial Cancer • Oncology • Solid Tumor • ER

Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study. (PubMed, Clin Exp Metastasis) - P | "In our study we evaluated the association of concomitant use of antibiotics (ATBs), proton pump inhibitors (PPIs), corticosteroids, statins, metformin and insulin with patient outcomes and we validated the prognostic role of a concomitant drug score in mUC patients treated with enfortumab vedotin (EV) monotherapy. In the Cox multivariate analysis, the concomitant drug score was a significant factor predicting both OS (HR = 1.32 [95% CI 1.03 - 1.68], p = 0.026) and PFS (HR = 1.23 [95% CI 1.01 - 1.51], p = 0.044). Our findings suggest detrimental impact of concomitant use of ATBs and corticosteroids on survival outcomes and the prognostic utility of the concomitant drug score in previously treated mUC patients receiving EV."

Journal • Real-world evidence • Retrospective data • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

5-Fluorouracil-based chemotherapy disrupts autophagy flux and protein synthesis in cultured myotubes: a role for mTORC1 signaling. (PubMed, Am J Physiol Cell Physiol) - "5-Fluorouracil-based chemotherapies, such as FOLFOX (5-fluorouracil, leucovorin, oxaliplatin), are used to treat colon cancer but also induce skeletal muscle toxicities...We also examined the effects of rapamycin or metformin administration on FOLFOX-induced disruptions to muscle protein synthesis and autophagy...We report that FOLFOX and oxaliplatin disrupt myotube mTORC1/AMPK regulation of autophagy flux, which was not easily reversible. However, rapamycin treatment increased autophagy flux in FOLFOX-treated myotubes."

Journal • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • FBXO32 • ULK1

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol. (PubMed, Lancet Oncol) - P2/3 | "We did not find significant evidence of an overall survival benefit of adding metformin to standard of care in the overall population of patients with metastatic hormone-sensitive prostate cancer. The side-effect profile of metformin was as expected and consisted mainly of diarrhoea. Adverse metabolic side-effects of ADT were significantly reduced in the metformin group compared with the standard of care group."

Journal • P3 data • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer. (PubMed, Gynecol Oncol) - P1 | "The results of this single-center clinical trial showed that, in patients with advanced or recurrent endometrial cancer, metformin can be safely added to temsirolimus providing limited response without added safety concerns."

Journal • P1 data • Anorexia • Dyslipidemia • Endometrial Cancer • Fatigue • Hematological Disorders • Hypertriglyceridemia • Mucositis • Oncology • Renal Disease • Solid Tumor • Thrombocytopenia

Safety and efficacy of olaparib combined to metronomic cyclophosphamide and metformin in recurrent advanced/metastatic endometrial cancer patients: ENDOLA trial (AACR 2022) - P1/2 | "In heavily pre-treated patients with advanced EC, olaparib 300 mg BID could be safely combined to metformin 1500 mg/day and metronomic cyclophosphamide 50 mg/day. With a 61.5% non-progression rate at 10 weeks, the 1st-objective was reached. The 5.1 month median PFS (7.5 for endometrioid and 4.3 for serous) is promising compared to those observed with chemotherapy or immunotherapy-based combination in KEYNOTE-775 (Colombo et al."

Clinical • Endometrial Cancer • Oncology • Sarcoma • Solid Tumor • IGF1

SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial (ESMO 2022) - P2 | "However, MF may have a modest effect on PSA dynamics and symptom control. Larger studies are needed for confirmation."

Clinical • Combination therapy • Late-breaking abstract • P2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Enhancing Curcumin Performance via PVP K30 Solid Dispersion: Synergistic Potential in Combination with Conventional Chemotherapeutic Agents in NSCLC Cells. (PubMed, AAPS PharmSciTech) - "This study aimed to optimize a solid dispersion of CUR with polyvinylpyrrolidone K30 (PVP K30) to enhance its biopharmaceutical properties and to evaluate its ability to enhance cytotoxic activity of conventional chemotherapeutic drugs (Afatinib, Cisplatin, and Metformin) in A549 NSCLC cells. Analysis of the combination index (CI) revealed synergistic interactions, as values less than 1 (CI < 1) were obtained for all combinations. These findings demonstrate that the use of solid dispersions significantly improves the solubility of CUR, potentially offering a promising strategy for enhancing the in vitro cytotoxic activity of conventional chemotherapeutic agents."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

1495: Old Drugs, New Tricks: The Reemergence of Drug Repurposing for Idiopathic Pulmonary Fibrosis (CHEST 2026) - "Expert presenters will review the pitfalls of prior efforts, explore how new technologies have enhanced precision in drug targeting, and discuss several promising candidates (including metformin, which is now under investigation in the forthcoming MAVRIC-IPF trial), offering hope for more accessible and impactful treatments...Examine the historical context of drug repurposing in IPF, including past failures, the success of nintedanib, and the potential of the emerging trial MAVRIC-IPF...3. Describe how advances in precision medicine, machine learning, and artificial intelligence are enhancing the efficiency and success of drug repurposing strategies in IPF."

Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases